Data analysis reveals limited efficacy, new development candidate announced
- Data from Phase 1B/2 study of lanraplenib in leukemia patients does not support continuing to Phase 2
- No complete response observed, but some patients showed blast reductions
- Kronos Bio has a new development candidate, KB-9558, targeting IRF4 in multiple myeloma
- KB-9558 currently in IND-enabling studies, expected to be completed in Q4 2024
- Kronos Bio’s cash runway expected to reach into 2026
Kronos Bio announced that the data from its Phase 1B/2 study of lanraplenib in patients with a type of leukemia does not support continuing the trial to Phase 2. While some patients showed blast reductions, no complete response was observed. In light of these findings, Kronos Bio has introduced a new development candidate, KB-9558, which targets IRF4 in multiple myeloma. KB-9558 is currently undergoing IND-enabling studies and is expected to be completed in the fourth quarter of 2024. Despite this setback, Kronos Bio remains confident in its financial position, with a cash runway projected to extend into 2026.
Public Companies: Kronos Bio (N/A)
Private Companies: undefined
Key People:
Factuality Level: 7
Justification: The article provides information about Kronos Bio’s Phase 1B/2 study of lanraplenib in patients with a type of leukemia. It states that the data does not support continuing the trial to Phase 2 and mentions the lack of complete response and early dropouts. It also mentions the company’s new development candidate, KB-9558, and its expected completion date. However, the article lacks specific details about the study design, methodology, and any potential limitations. Therefore, while it provides some factual information, it could benefit from more comprehensive reporting.
Noise Level: 3
Justification: The article provides information about Kronos Bio’s Phase 1B/2 study of lanraplenib in patients with leukemia. It mentions that the data does not support continuing the trial to Phase 2 and provides details about the study and the company’s new development candidate. However, the article lacks scientific rigor and intellectual honesty as it does not provide any specific data or evidence to support its claims. It also does not explore the consequences of the trial results on patients or hold the company accountable. Overall, the article contains some relevant information but lacks depth and analysis.
Financial Relevance: Yes
Financial Markets Impacted: The news article pertains to a biopharmaceutical company, Kronos Bio, and its lead drug candidate lanraplenib. The discontinuation of the Phase 1B/2 study of lanraplenib may impact the company’s future prospects and potential revenue.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article does not mention any extreme events or their impact.
www.marketwatch.com 
